Editas Medicine (EDIT) Accumulated Expenses (2015 - 2025)

Editas Medicine (EDIT) has reported Accumulated Expenses for 11 consecutive years, with $32.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses fell 28.89% year-over-year to $32.6 million; the TTM figure through Dec 2025 stood at $32.6 million (down 28.89% YoY), while the FY2025 annual figure was $32.6 million, down 28.89% from the prior year.
• Accumulated Expenses declined to $32.6 million in Q4 2025 per EDIT's latest filing, from $47.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $48.1 million in Q2 2025 and bottomed at $14.6 million in Q3 2021.
• Historically, Accumulated Expenses has averaged $29.4 million across 5 years, with a median of $29.5 million in 2023.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 99.91% — and 2025, when it fell 28.89%.
• Editas Medicine's Accumulated Expenses stood at $20.2 million in 2021, then jumped by 54.99% to $31.3 million in 2022, then grew by 10.44% to $34.6 million in 2023, then surged by 32.68% to $45.9 million in 2024, then declined by 28.89% to $32.6 million in 2025.
• Business Quant data shows EDIT's Accumulated Expenses at $32.6 million in Q4 2025, $47.5 million in Q3 2025, and $48.1 million in Q2 2025.